A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
1997/01/23 by Michael J. Fine, Thomas E. Auble, Donald M. Yealy +6 · 4,682 citations
Medicine · #Clinical prediction rule #Cohort #Cohort study #Community-acquired pneumonia #Confidence interval #Internal medicine #Medicine #Nosocomial Infections in ICU #Pediatrics #Pneumonia #Pneumonia and Respiratory Infections #Pneumonia severity index #Sepsis Diagnosis and Treatment
paper · pdf · doi:10.1056/nejm199701233360402
published in New England Journal of Medicine 336(4), 243-250 (Massachusetts Medical Society)
openalex publication_date 1997/01/23 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Abstract
BACKGROUND: There is considerable variability in rates of hospitalization of patients with community-acquired pneumonia, in part because of physicians' uncertainty in assessing the severity of illness at presentation. METHODS: From our analysis of data on 14,199 adult inpatients with community-acquired pneumonia, we derived a prediction rule that stratifies patients into five classes with respect to the risk of death within 30 days. The rule was validated with 1991 data on 38,039 inpatients and with data on 2287 inpatients and outpatients in the Pneumonia Patient Outcomes Research Team (PORT) cohort study. The prediction rule assigns points based on age and the presence of coexisting disease, abnormal physical findings (such as a respiratory rate of > or = 30 or a temperature of > or = 40 degrees C), and abnormal laboratory findings (such as a pH <7.35, a blood urea nitrogen concentration > or = 30 mg per deciliter [11 mmol per liter] or a sodium concentration <130 mmol per liter) at presentation. RESULTS: There were no significant differences in mortality in each of the five risk classes among the three cohorts. Mortality ranged from 0.1 to 0.4 percent for class I patients (P=0.22), from 0.6 to 0.7 percent for class II (P=0.67), and from 0.9 to 2.8 percent for class III (P=0.12). Among the 1575 patients in the three lowest risk classes in the Pneumonia PORT cohort, there were only seven deaths, of which only four were pneumonia-related. The risk class was significantly associated with the risk of subsequent hospitalization among those treated as outpatients and with the use of intensive care and the number of days in the hospital among inpatients. CONCLUSIONS: The prediction rule we describe accurately identifies the patients with community-acquired pneumonia who are at low risk for death and other adverse outcomes. This prediction rule may help physicians make more rational decisions about hospitalization for patients with pneumonia.
Cited by
- Community-Acquired Pneumonia
- Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study
- Markers of treatment failure in hospitalised community acquired pneumonia
- Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
- Predicting Respiratory Disease Mortality Risk Using Open-Source AI on Chest Radiographs in an Asian Health Screening Population
- Clinical Diagnosis of Legionella Pneumonia Revisited: Evaluation of the Community-Based Pneumonia Incidence Study Group Scoring System
- Host-directed immune therapies: a second front in the battle against sepsis
- Derivation and validation of a point-based forecasting tool for SARS-CoV-2 critical care occupancy: a population-based modeling study
- Association Between Elevated Neutrophil-to-Lymphocyte Ratio and Mortality Risk in Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
- Validation of a clinical prognostic model to identify low‐risk patients with pulmonary embolism
- The Treaty Protection of Religious Rights: U.N. Draft Convention on the Elimination of All Forms of Intolerance and of Discrimination Based on Religion or Belief
- Predicting Mortality Risk in Viral and Unspecified Pneumonia to Assist Clinicians with COVID-19 ECMO Planning
- Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia
- Improved Diagnosis of the Etiology of Community-Acquired Pneumonia with Real-Time Polymerase Chain Reaction
- Evaluation of the Immunochromatographic Binax NOW Assay for Detection ofStreptococcus pneumoniaeUrinary Antigen in a Prospective Study of Community‐Acquired Pneumonia in Spain
- Binary Classifier Calibration: Bayesian Non-Parametric Approach
- 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia
- A multidisciplinary consensus on dehydration: definitions, diagnostic methods and clinical implications
- The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America
- A Bayesian Network Classifier that Combines a Finite Mixture Model and a Naive Bayes Model
- Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials
- Comparison of Four Clinical Prediction Rules for Estimating Risk in Heart Failure
- Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. [europepmc]
- Community-acquired pneumonia. [europepmc]
- Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. [europepmc]
- Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. [europepmc]
- Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. [europepmc]
- Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. [europepmc]
- Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. [europepmc]
- Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. [europepmc]
- The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. [europepmc]
- Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. [europepmc]
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. [europepmc]
- Community-acquired pneumonia. [europepmc]
- Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. [europepmc]
- Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. [europepmc]
- Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults. [europepmc]
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. [europepmc]
- Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. [europepmc]
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. [europepmc]
- The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. [europepmc]
- Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults with COVID-19. [europepmc]
- SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. [europepmc]
- Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. [europepmc]
- Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. [europepmc]
- Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. [europepmc]
- COVID-19 and liver disease: mechanistic and clinical perspectives. [europepmc]
Related